Peiyang Zhou1, Zuneng Lu2, Ping Gao3, Puqing Wang3, Zhihua Cao3, Guibin Zhang3, Shouan Wang3, Yuhua Feng3, Pu Wang3. 1. Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, People's Republic of China; Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, Hubei Province, People's Republic of China. 2. Department of Neurology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, People's Republic of China. Electronic address: zuneng_lu@163.com. 3. Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, Hubei Province, People's Republic of China.
Abstract
OBJECTIVES: The purpose of this study is to validate the efficacy of intensive statin therapy for patients with atherosclerotic intracranial arterial stenosis (AICAS). METHODS: In this study, we performed a single-center, randomized, single-blind, parallel-group clinical trial. A total of 120 Chinese patients with AICAS were enrolled and randomly divided into three groups [low-dose atorvastatin therapy (LAT, 10mg/day), standard-dose atorvastatin therapy (SAT, 20mg/day), and intensive-dose atorvastatin therapy (IAT, 40mg/day) groups] in a 1:1:1 ratio. Evaluation variables, including changes in serum lipid profiles, degree of stenosis, and perfusion-related parameters derived from computed tomography perfusion (CTP) imaging from baseline to weeks 26 and 52, as well as the occurrence of cerebrovascular events during the study period, were used to compare the benefits of these three statin therapies. RESULTS: After 52 weeks of treatment, improvement of serum lipid profiles, degree of stenosis, and perfusion-related parameters were all significantly better in the IAT group. In addition, the cumulative probability of cerebrovascular events at 52 weeks was significantly lower in the IAT group than in the LAT group, although there was no statistical difference between the IAT group and the SAT group. The proportion of patients experiencing any adverse event was similar among the three treatment groups. Adverse events caused by IAT were generally mild; no serious adverse events occurred throughout the entire period of study. CONCLUSION: In conclusion, long-term use of IAT appears to be a safe and effective treatment at least for Chinese patients with AICAS.
RCT Entities:
OBJECTIVES: The purpose of this study is to validate the efficacy of intensive statin therapy for patients with atherosclerotic intracranial arterial stenosis (AICAS). METHODS: In this study, we performed a single-center, randomized, single-blind, parallel-group clinical trial. A total of 120 Chinese patients with AICAS were enrolled and randomly divided into three groups [low-dose atorvastatin therapy (LAT, 10mg/day), standard-dose atorvastatin therapy (SAT, 20mg/day), and intensive-dose atorvastatin therapy (IAT, 40mg/day) groups] in a 1:1:1 ratio. Evaluation variables, including changes in serum lipid profiles, degree of stenosis, and perfusion-related parameters derived from computed tomography perfusion (CTP) imaging from baseline to weeks 26 and 52, as well as the occurrence of cerebrovascular events during the study period, were used to compare the benefits of these three statin therapies. RESULTS: After 52 weeks of treatment, improvement of serum lipid profiles, degree of stenosis, and perfusion-related parameters were all significantly better in the IAT group. In addition, the cumulative probability of cerebrovascular events at 52 weeks was significantly lower in the IAT group than in the LAT group, although there was no statistical difference between the IAT group and the SAT group. The proportion of patients experiencing any adverse event was similar among the three treatment groups. Adverse events caused by IAT were generally mild; no serious adverse events occurred throughout the entire period of study. CONCLUSION: In conclusion, long-term use of IAT appears to be a safe and effective treatment at least for Chinese patients with AICAS.
Authors: Tanya N Turan; Osama O Zaidat; Gary S Gronseth; Marc I Chimowitz; Antonio Culebras; Anthony J Furlan; Larry B Goldstein; Nestor R Gonzalez; Julius G Latorre; Steven R Messé; Thanh N Nguyen; Rajbeer S Sangha; Michael J Schneck; Aneesh B Singhal; Lawrence R Wechsler; Alejandro A Rabinstein; Mary Dolan O'Brien; Heather Silsbee; Jeffrey J Fletcher Journal: Neurology Date: 2022-03-22 Impact factor: 9.910
Authors: Marios Psychogios; Alex Brehm; Elena López-Cancio; Gian Marco De Marchis; Elena Meseguer; Aristeidis H Katsanos; Christine Kremer; Peter Sporns; Marialuisa Zedde; Adam Kobayashi; Jildaz Caroff; Daniel Bos; Sabrina Lémeret; Avtar Lal; Juan F Arenillas Journal: Eur Stroke J Date: 2022-06-03